Your session is about to expire
← Back to Search
Device
Low Level Laser Therapy for Bowel Incontinence (LLLT-FI Trial)
N/A
Recruiting
Led By Jihong Chen, MD PhD
Research Sponsored by McMaster University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients with fecal incontinence
Must not have
Active bleeding in area of treatment
Known malignancies in the area of treatment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 and 12 weeks
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a special light therapy to help people who can't control their bowel movements and haven't been helped by other treatments. The therapy involves multiple sessions over a few weeks. Researchers will check if it improves symptoms and quality of life by looking at questionnaires and physical tests.
Who is the study for?
This trial is for individuals with severe fecal incontinence, which means they have trouble controlling their bowel movements. It's not open to pregnant people, those on steroids, anyone with active deep vein thrombosis or bleeding in the treatment area, light-sensitive patients, or if there are tattoos or known cancers where the therapy will be applied.
What is being tested?
The study is testing low level laser therapy (LLLT) to see if it helps patients with severe refractory fecal incontinence. There isn't a placebo group being compared against; this is an initial test of the concept to understand its effects.
What are the potential side effects?
Since LLLT doesn't involve drugs and uses low-intensity lasers, side effects might include local skin irritation at the site of application. However, specific side effect profiles will be studied as part of this trial.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I experience loss of bowel control.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am currently experiencing bleeding in the area that needs treatment.
Select...
I have cancer in the area where treatment is planned.
Select...
I currently have a deep vein thrombosis.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 4 and 12 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 and 12 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in number of fecal incontinence episodes
Secondary study objectives
Change in Quality of Life
Change in anal sphincter tone
Change in increase of anal sphincter pressure during squeezing
+2 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Incontinence and low level laser therapyExperimental Treatment1 Intervention
Intervention: Low level laser therapy (sacral neuromodulation or photobiomodulation) will be administered to patients with fecal incontinence
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Low level laser therapy (LLLT)
2021
N/A
~200
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for bowel incontinence include anal bulking agents, endoanal electrical stimulation with biofeedback, and low-level laser therapy. Anal bulking agents work by increasing the bulk of the anal canal, thereby improving sphincter function.
Endoanal electrical stimulation with biofeedback helps strengthen the pelvic floor muscles and improve coordination. Low-level laser therapy stimulates cellular function, reduces inflammation, and promotes tissue repair.
These mechanisms are crucial for bowel incontinence patients as they address the underlying issues of muscle weakness, tissue damage, and inflammation, leading to improved control and quality of life.
Administration of an Anal Bulking Agent With Polyacrylate-Polyalcohol Copolymer Particles Versus Endoanal Electrical Stimulation With Biofeedback for the Management of Mild and Moderate Anal Incontinence: A Randomized Prospective Study.Combined application of chondroitinase ABC and photobiomodulation with low-intensity laser on the anal sphincter repair in rabbit.Systematic Review of Surgical Treatments for Fecal Incontinence.
Administration of an Anal Bulking Agent With Polyacrylate-Polyalcohol Copolymer Particles Versus Endoanal Electrical Stimulation With Biofeedback for the Management of Mild and Moderate Anal Incontinence: A Randomized Prospective Study.Combined application of chondroitinase ABC and photobiomodulation with low-intensity laser on the anal sphincter repair in rabbit.Systematic Review of Surgical Treatments for Fecal Incontinence.
Find a Location
Who is running the clinical trial?
McMaster UniversityLead Sponsor
918 Previous Clinical Trials
2,616,273 Total Patients Enrolled
Jihong Chen, MD PhDPrincipal InvestigatorMcMaster University
1 Previous Clinical Trials
20 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have tattoos in the area where the treatment will be done.I am currently experiencing bleeding in the area that needs treatment.You are sensitive to light.I am currently taking steroids.You are pregnant.I have cancer in the area where treatment is planned.I currently have a deep vein thrombosis.I experience loss of bowel control.
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Research Study Groups:
This trial has the following groups:- Group 1: Incontinence and low level laser therapy
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.